Sign In
Buy ZYNE
$1.30
+0 (+0%)
At Close: Jan 09, 2024
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
12:30pm, Tuesday, 15'th Nov 2022 GlobeNewswire Inc.
DEVON, Pa., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsych
Zynerba Pharmaceuticals granted orphan drug designation by EC for Zygel active ingredient to treat 22q
10:02am, Tuesday, 15'th Nov 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) reported it has further advanced its transdermal gel Zygel—receiving orphan drug designation from the European Commission (EC) for the gel's active ingredie
Zynerba ends 3Q with robust $55.9M cash runway to advance its Zygel CBD Gel for Fragile X Syndrome
09:41am, Monday, 14'th Nov 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), which works on innovative pharmaceutically produced transdermal cannabinoid therapies for neuropsychiatric disorders, posted results for the third quarter th
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
11:30am, Wednesday, 02'nd Nov 2022 GlobeNewswire Inc.
DEVON, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsych
Zynerba Pharmaceuticals gets another US Patent for its transdermal cannabidiol product candidate, Zygel
08:13am, Wednesday, 02'nd Nov 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has announced that the US Patent and Trademark Office has issued Patent No. 11,458,109, titled "Treatment of 22q11.2 Deletion Syndrome With Cannabidiol," whic
Zynerba Pharma presents positive data from Phase 2 INSPIRE trial at NORD Rare Diseases and Orphan Products Breakthrough Summit
08:03am, Monday, 17'th Oct 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held Oc
Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
11:00am, Monday, 10'th Oct 2022 GlobeNewswire Inc.
DEVON, Pa., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsych
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
11:00am, Thursday, 06'th Oct 2022 GlobeNewswire Inc.
DEVON, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsych
Zynerba Pharmaceuticals receives new US patent for its cannabidiol formulated gel Zygel
08:13am, Thursday, 06'th Oct 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has boosted its international intellectual property (IP) portfolio, revealing it has been granted a new US patent for its cannabidiol-formulated gel Zygel. Th
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
11:00am, Thursday, 22'nd Sep 2022 GlobeNewswire Inc.
DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsyc
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
07:00am, Thursday, 22'nd Sep 2022
DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychi
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium
01:15pm, Thursday, 08'th Sep 2022 GlobeNewswire Inc.
INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profile INSPIRE trial in 22q
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has announced an oral presentation at the Society for the Study of Behavioural Phenotypes' 24th International Research Symposium, being held in Oslo, Norway,
Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference
07:00am, Tuesday, 06'th Sep 2022
DEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychi
Why Micro Focus International Is Trading Higher By Around 94%; Here Are 28 Stocks Moving Premarket
10:53am, Friday, 26'th Aug 2022 Benzinga
Gainers
Micro Focus International plc (NYSE: MFGP) shares rose 93.6% to $6.06 in pre-market trading after the company reached an agreement with Open Text Corporation (NASDAQ: OTEX) to be acquired fo
